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According to Berenblum’s two-stage hypothesis, the first stage in carcinogenesis is the
production of benign premalignant lesions. Between this initiation stage and the
formation of a malignant tumor there is often a long lag phase. We propose that this
lag is caused by the delay in the formation of a new and rare tumor-specific antigen,
which induces an immune response that stimulates tumor growth. Such tumor-specific
antigens could arise as a result of a mutator-like phenotype, which is supposedly
present in the benign initial stage of carcinogenesis. According to this hypothesis, the
first stage lesion provides a weakly mutagenic environment conducive to the formation
of the new antigen(s). If no such new antigens appear so there is no consequent
immune response, it is argued that carcinogenesis would seldom if ever ensue.Background
The phenomenon upon which this discussion is based is nicely summarized in a paper
by Brash and Cairns [1], a short section of which is reproduced here: “. . . Humans and
animals show the same strange relationship between dose of carcinogen and time of
appearance of their cancers. For example, although the incidence of lung cancer in
smokers appears to be directly proportional to the number of cigarettes smoked per
day [2], it is proportional to roughly the sixth power of the duration of smoking.
Similarly, when rats are continuously exposed to dietary carcinogens their incidence of
cancer rises as the first or second power of dose rate but as a much higher power of
time [3,4] . . . smokers keep their raised rate of lung cancer for many years after they
have stopped smoking [5] . . . These numerous experiments suggest, therefore, that
mutagenic carcinogens cause just one or two events and these (like the initial event in
in vitro carcinogenesis) are then followed by steps that accumulate solely with the
passage of time, driven perhaps by cell division [6]. . .”.
In the present paper we review the probability that the frequently observed time lag
in carcinogenesis is caused by the delay in the formation of a new tumor-specific anti-
gen that, in turn, induces a tumor-stimulating immune response [7]. This tumor-
specific antigen is postulated to arise as a result of a mutator-like phenotype that we
postulate exists in the benign first stage of the carcinogenic mechanism [7,8].
In 1949–50, when one of the present authors (RTP) joined the laboratory of the late
Dr. H.B. Andervont as a fellow at the National Cancer Institute, interest was very low
in all aspects of immunity in relation to cancer. In fact, in about 1956, RTP was told
by the head of the National Cancer Institute that “you would be well advised to find
some other topic for your investigations, many a career has been dashed on those hard© 2013 Prehn and Prehn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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it was probably sound and proper advice at that time. After the paper of Prehn and
Main in 1957 [9], followed shortly by that of the Karolinska group showing that tumor-
specific immunity was possible against a methylcholanthracine-induced sarcoma even
in the autologous mouse [10], the immune surveillance hypothesis became popular and
has remained so to the present day.Role of the mutator phenotype in carcinogenesis
The recent discovery of thousands of mutations in each cancer has suggested one
plausible explanation for the often long delay in carcinogenesis; an ongoing mutagenic
environment was probably created during an earlier exposure to mutagens (in all
likelihood by the failure, via mutation, of a gene repair mechanism [8]). The resulting
mutator phenotype would eventually and inevitably result in a combination of mutants
that must grow as a cancer. This hypothesis accounts nicely for the lag so often seen in
carcinogenesis. Other mechanisms to enhance carcinogenic accumulations have also
been proposed [11-13], but the question remains - is there some further plausible
explanation for the sometimes long delay beyond the time required for the mere
accumulation of a carcinoma genome? Present data suggest that such an explanation
may reside within the immune system.Role of the immune system in oncogenesis
A further hypothesis that might corroborate the mutator phenotype hypothesis is a
gradual decline in the strength of the immune mechanisms with age; a decline in
immunity would eventually result in a cluster of mutations that would be able to grow
in that weakened immune environment. Under this hypothesis, the role of time can be
accounted for by the known decline in immune mechanisms in adults with increasing
age [14]. It also is apparent that the incidence of most cancers rises with increasing age;
it is obvious that these facts could be causally related.
We have previously published evidence suggesting that the primary role of the
immune reaction in carcinogenesis is to stimulate rather than to inhibit cancer growth
[15]. This stimulatory role for immunity in no way negates the idea that a decline in
the immune capacity of the host may cause the eventual appearance of a cancer.
Immunostimulation is dependent upon the quantitative ratio of immune reactants to
tumor size; in general - up to a point - the weaker the immune mechanism, the greater
the stimulatory effect on tumor growth. Thus, the weaker immunity in the aged might
well be stimulatory to incipient cancers [16].
Until recently, it seemed very unlikely that immune mechanisms could affect human
tumorigenesis because immune effects seemed largely confined to relatively rare
carcinogen- or virus-induced cancers [17]. Hewitt was vociferous on the subject; he
went so far as to publish his failed attempt to demonstrate the induction of immune
inhibition in seven different spontaneous cancers in mice; the only effect of his
immunization attempts was that, in all seven cases that he tested, the tumors grew
better in the presumptively immunized syngeneic mice than in the non-immunized
controls [17]! This same stimulation of the growths of implants in specifically
immunized recipients was confirmed using a new set of spontaneous mouse tumors by
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specific antigens on his spontaneously-derived tumors. However, we interpreted the
stimulation as showing the presence of low levels of tumor-specific antigens that
produced weakly stimulatory rather than inhibitory concentrations of immune reactants.
As already mentioned, in 1972 RTP had made the counterintuitive observation that small
numbers of spleen cells from tumor immune mice could, when mixed with the target
tumor, sped rather than inhibited the growth of the mixture when it was implanted into
immunodepressed syngeneic recipients [15]. Apparently the immune system is subject to
some form of hormesis because larger quantities of immune cells, when used in like
manner, markedly inhibited the cancer’s growth [19]. This observation has, in essence,
been confirmed by many others [20-22] and is central to the present formulation.The two-stage hypothesis
In the 1950s, a major topic of discussion was the idea put forth by Friedewald and Rous
[23], and further developed by Berenblum and Shubic [24], that carcinogenesis could
be divided into two quite different and distinct stages. There has been much subse-
quent argument about the phenomenon, but it is widely agreed that it is real, at least in
many situations. The essence of the proposal is that if a sub-carcinogenic dosage of a
carcinogen is followed by one of a number of non-carcinogenic irritants, cancers may
then be produced; classically, a subcarcinogenic dosage of a hydrocarbon carcinogen
(the initiator), followed by paintings of the same skin area with the non-carcinogenic
irritant, croton oil (the promoter). The initiating effect was shown to be very long
lasting. However, reversal of the application sequence yielded no observable carcino-
genic effect in most studies. Students in our laboratory devised another method that
used skin grafting as a promoter [25,26].
According to Berenblum’s two-stage hypothesis [24], the first stage is the production
of benign premalignant lesions. We postulate that the second stage is a small immune
response to rare new antigens on a previously benign first stage (papilloma?) cell, which
stimulates that cell to multiply as a malignant tumor. According to this hypothesis, the
papilloma or other benign first stage lesion would itself provide an environment
conducive to the formation of new antigens (a weakly mutagenic environment); in the
absence of such new antigens and the consequent immune response to them, carcino-
genesis would, according to the work of Andrews, seldom if ever occur [7,26].
Andrews’s two stages produced no cancers but many regressing benign papillomas in
mice that had been maximally immunodepressed [27]. To achieve an immunological
cancer cure, one would apparently have to supply the patient with a large enough
immune reaction to inhibit rather than stimulate tumor growth. Alternatively, perhaps
one could inhibit tumor growth by drastically reducing the immune reaction.Conclusions
Cancer formation probably depends upon a new antigenicity that arouses a weak but
stimulatory immunity to a new tumor antigen - an antigen that arose as a kink in the
benign cells that had been induced in the first stage of the two stage carcinogenic
process [7]. This kinked two stage hypothesis accounts rather neatly for the time lag in
the carcinogenic mechanism.
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quantities of immunity is now well established [20-22], though the mechanism of this
stimulatory effect remains obscure. A possible explanation may reside in work of Rubin
showing that cellular growth is inhibited by interactions with surrounding normal cells
[28]; perhaps a small amount of immunity can interfere with this inhibitory reaction
and thus appear to stimulate [29].
Possible mechanisms of immunostimulation have also been discussed by Parmiani
[30]. We acknowledge that immunity is a very complex phenomenon; many diferent
types of immune cells have been described and, although in this paper we have
emphasized the overriding importance of the quantitative relationship between the
target and immunity, we admit that among the complexities of the response are
individual elements that may be stimulatory while others are inhibitory to tumor
growth [31-33]. It seems possible to us that whether an immune effector becomes a
morphologically recognizable inhibitor or stimulator might even be determined, at least
in part, by the afore mentioned quantitatve relationship, albeit that we have little
evidence for such an effect.
It seems probable that selection might, in most cases, keep a weak immune reaction
at nearly optimal levels for tumor growth indefinitely. However, the fact that a
depressed level of immunity increases the growth of some tumor types in humans
[34,35] suggests that such tumors may not have originally enjoyed the optimal immu-
nity for the fastest possible tumor growth.
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